Take a look through the key trials investigating BCG/ICI combinations in BCG-naïve NMIBC. In BCG-naïve non–muscle invasive bladder cancer (NMIBC), emerging options are largely focused on combining BCG ...
The Virtuoso Surgical Robotic System received FDA breakthrough designation for bladder lesion removal, enabling expedited development and review processes. En bloc resection improves cancer staging ...
A major focus of the discussion is the integration of advanced prostate cancer therapeutics into urology offices. In this episode of Pearls and Perspectives, Amy Pearlman, MD, speaks with Vahan ...
Ensuring consistent diagnostic quality remains critical. In this video, Veeru Kasivisvanathan, MBBS, BSc, FRCS, MSc, PGCert, PhD, discussed findings from the PRIME trial, a multicenter international ...
Several experts share their thoughts on the impact of the gemcitabine intravesical system for BCG-unresponsive NMIBC. On September 9, 2025, the FDA approved the gemcitabine intravesical system ...
BioTraceIO360 received FDA 510(k) clearance for kidney ablation, expanding its previous liver tumor ablation indication. The platform standardizes minimally invasive care, enhancing treatment planning ...
Stephen J. Freedland, MD, placed dietary guidance within the broader context of survivorship care. In discussing the links between diet and prostate cancer, Stephen J. Freedland, MD, a professor of ...
The Signatera ctDNA test predicts which MIBC patients benefit from adjuvant atezolizumab, showing significant DFS and OS improvements in MRD-positive patients. The IMvigor011 trial enrolled 760 ...
Combining BCG with ICIs targets the PD-1/PD-L1 pathway to overcome BCG resistance in NMIBC. The CREST trial showed improved event-free survival with BCG plus sasanlimab compared to BCG alone. Future ...
Enzalutamide plus ADT significantly reduced the risk of radiographic progression or death and castration resistance compared to darolutamide plus ADT in mHSPC patients. The MAIC analysis provided a ...
NCCN guideline-recommended treatments significantly reduce prostate cancer mortality compared to other causes, even in high-risk patients. The study involved 135,636 Swedish patients, with 46% ...
UGN-102's NDA is supported by the phase 3 ENVISION trial, showing a 79.6% complete response rate at 3 months for LG-IR-NMIBC patients. The FDA is evaluating if the observed duration of response is due ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback